Please login first
Antonio Araujo  - - - 
Publication Record
Distribution of Articles published per year 
(1998 - 2018)
Total number of journals
published in
Publications See all
Article 0 Reads 0 Citations Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor Marta Rocha, João Correia De Sousa, Marta Salgado, António A... Published: 17 December 2018
GE - Portuguese Journal of Gastroenterology, doi: 10.1159/000494569
DOI See at publisher website ABS Show/hide abstract
Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some advanced malignancies, they are also associated with a significant risk of immune-related adverse events. These adverse events can occur in any organ system, but gastrointestinal side effects are among the most commonly reported, with manifestations ranging from mild diarrhoea to severe colitis, sharing some features with inflammatory bowel disease. Anticipating a greater use of these drugs in the future, gastroenterologists should expect to be increasingly faced with gastrointestinal immune-related adverse events. Knowledge of these toxicities, as well as effective management algorithms, is essential to enable early diagnosis and treatment, decreasing morbidity and mortality. We reviewed the currently available literature on gastrointestinal toxicity induced by immune checkpoint inhibitors, namely the clinical features, diagnosis, and management.
Article 0 Reads 0 Citations Is There a Surplus of Non-Specialist Physicians in Portugal or Just Poor Human Resources Planning? Francisco Ribeiro-Mourão, António Araújo, Carlos Cortes, Tia... Published: 30 November 2018
Acta Médica Portuguesa, doi: 10.20344/amp.11273
DOI See at publisher website
Article 0 Reads 3 Citations Okra mucilage and corn starch bio-based film to be applied in food Antonio Araújo, Andrêssa Galvão, Carlos Silva Filho, Francis... Published: 01 October 2018
Polymer Testing, doi: 10.1016/j.polymertesting.2018.09.010
DOI See at publisher website
Article 0 Reads 0 Citations Merkel cell carcinoma and the challenge in its approach Filipe Coutinho, Miguel Horta, Estrela Rocha, Carlos Vasconc... Published: 01 August 2018
Porto Biomedical Journal, doi: 10.1016/j.pbj.0000000000000011
DOI See at publisher website
Article 0 Reads 0 Citations CSF-1 and Ang-2 serum levels — prognostic and diagnostic partners in non-small cell lung cancer Ana Luísa Coelho, Mónica Patrícia Gomes, Raquel Jorge Catari... Published: 25 July 2018
ESMO Open, doi: 10.1136/esmoopen-2018-000349
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Lung cancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results encompass only 30%–40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lung cancer (NSCLC) prognosis and whether these could serve as biomarkers for NSCLC detection, along with Ang-2. We prospectively studied an unselected cohort of 145 patients with NSCLC and a group of 30 control individuals. Serum levels of Ang-2 and CSF-1 were measured by ELISA prior to treatment. Serum levels of CSF-1 and Ang-2 are positively correlated (p<0.000001). Individuals with high serum levels of CSF-1 have a 17-fold risk for NSCLC presence and patients with combined High Ang-2/CSF-1 serum levels present a 5-fold increased risk of having NSCLC. High Ang-2/CSF-1 phenotype is also associated with worst prognosis in NSCLC. Combined expression of CSF-1 and Ang-2 seems to contribute to worst prognosis in NSCLC and it is worthy to understand the basis of this unexplored partnership. Moreover, we think CSF-1 could be included as a biomarker in NSCLC screening protocols that can improve the positive predictive value of the current screening modalities, increase overall cost effectiveness and potentially improve lung cancer survival.
Article 0 Reads 0 Citations Potential and importance of metalloproteinases and interleukins in inflammation and metastasization in non-small cell lu... João Luís Pereira, Monica Gomes, Ana Luísa Teixeira, Ana Coe... Published: 01 June 2018
Translational Cancer Research, doi: 10.21037/tcr.2018.05.16
DOI See at publisher website